Copyright
©The Author(s) 2022.
World J Gastroenterol. Dec 7, 2022; 28(45): 6421-6432
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6421
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6421
Table 1 Clinicohistopathologic features of the pancreatic acinar cell carcinoma patients in this dataset (n = 11)
| Characteristic | Number of patients (%) |
| Male | 11 (100) |
| Median age at diagnosis, yr | 65 (56.5-74.0) |
| Median tumor size, cm | 7.0 (2.7-16.4) |
| Histology | |
| Pure acinar | 6 (55) |
| Mixed acinar-neuroendocrine | 3 (27) |
| Mixed acinar-ductal | 2 (18) |
| Primary tumor site | |
| Head/uncinate | 4 (37) |
| Body | 2 (18) |
| Tail | 5 (45) |
| Stage | |
| Resectable | 2 (18) |
| Locally advanced | 2 (18) |
| Metastatic | 7 (64) |
| 1st line treatment | |
| Surgery only | 1 (9) |
| Surgery and chemotherapy | 2 (18) |
| Preoperative chemoradiotherapy and surgery | 1 (9) |
| Chemotherapy only | 7 (64) |
| Palliative chemotherapy | |
| Modified FOLFIRINOX | 6 (60) |
| Gemcitabine with Nab-paclitaxel | 3 (30) |
| Gemcitabine | 1 (10) |
- Citation: Lee CL, Holter S, Borgida A, Dodd A, Ramotar S, Grant R, Wasson K, Elimova E, Jang RW, Moore M, Kim TK, Khalili K, Moulton CA, Gallinger S, O’Kane GM, Knox JJ. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature. World J Gastroenterol 2022; 28(45): 6421-6432
- URL: https://www.wjgnet.com/1007-9327/full/v28/i45/6421.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i45.6421